Digestive Endoscopy Unit, Pôle Digestif Paris Bercy, Clinique Paris-Bercy, Charenton-le-Pont, France
Digestive Endoscopy Unit, Pôle Digestif Paris Bercy, Clinique Paris-Bercy, Charenton-le-Pont, France.
Gut. 2020 Dec;69(12):2159-2164. doi: 10.1136/gutjnl-2019-319565. Epub 2020 Mar 24.
Endocuff Vision (ECV) is the second generation of a device designed to improve polyp detection. The aim of this study was to evaluate its impact on adenoma detection rate (ADR) in routine colonoscopy.
This cluster-randomised crossover trial compared Endocuff-assisted (ECV+) with standard (ECV-) colonoscopy. Two teams of 11 endoscopists each with prior ECV experience, balanced in terms of basal ADR, gender and case volume were compared. In randomised fashion, the teams started with ECV+ or ECV- and switched group after inclusion of half of the cases. The main outcome criterion was ADR difference between ECV+ and ECV-. Subgroup analysis was done for physicians with low and high ADR (< or ≥ 25%).
During two periods of 20 and 21 weeks, respectively, the 22 endoscopists included 2058 patients (1032 ECV- vs 1026 ECV+, both groups being comparable). Overall ADR for both groups taken together was higher with ECV (39.2%) than without (29.4%; p<0.001) irrespective of the sequence of use (ECV+ or ECV- first), but mostly in adenomas <1 cm. In the physician subgroup analysis, only high detectors showed a significant ADR increase (from 31% to 41%, p<0.001), while the increase in the low detectors was not significant (from 24% to 30%, p=0.11). ECV had a positive impact in all colonic locations, except for the rectum. No ECV- related complication was reported.
We observed a significant ADR difference of approximately 10% by the use of ECV. By subgroup analysis, this increase was significant only in physicians classified as high detectors.
ClinicalTrials.gov (NCT03344055).
Endocuff Vision(ECV)是一种旨在提高息肉检测率的设备的第二代产品。本研究旨在评估其对常规结肠镜检查中腺瘤检测率(ADR)的影响。
这是一项采用分组随机交叉设计的临床试验,比较了 Endocuff 辅助(ECV+)与标准(ECV-)结肠镜检查。由两组各 11 名内镜医师组成,每组内镜医师均具有 ECV 检查经验,且在 ADR、性别和病例量方面均具有可比性。内镜医师以随机方式先进行 ECV+或 ECV-检查,在纳入一半病例后再切换组别。主要观察指标为 ECV+与 ECV-之间的 ADR 差异。对 ADR 较低(<25%)和较高(≥25%)的医生进行亚组分析。
在分别为 20 周和 21 周的两个时间段内,22 名内镜医师共纳入 2058 例患者(ECV-组 1032 例,ECV+组 1026 例,两组患者具有可比性)。两组患者总体 ADR 均较高,ECV 组为 39.2%,无 ECV 组为 29.4%(p<0.001),且无论使用顺序(ECV+或 ECV- 先行)如何,差异均有统计学意义,但主要发生在<1cm 的腺瘤中。在医生亚组分析中,只有高检测者的 ADR 显著增加(从 31%增加至 41%,p<0.001),而低检测者的 ADR 增加无统计学意义(从 24%增加至 30%,p=0.11)。ECV 对所有结直肠部位(直肠除外)均有积极影响。未报告 ECV 相关并发症。
我们观察到使用 ECV 后 ADR 差异约为 10%。亚组分析显示,只有被归类为高检测者的医生 ADR 增加具有统计学意义。
ClinicalTrials.gov(NCT03344055)。